These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 3064267)
1. [Immunohistochemical tumor diagnosis in breast cancer--use for assessing the stage and biology of so-called "small breast cancer"]. Schauer A; Rothe H; Balzer I; Fiebig I; Rauschecker H Rontgenblatter; 1988 Aug; 41(8):340-4. PubMed ID: 3064267 [TBL] [Abstract][Full Text] [Related]
2. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors. Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Landberg G; Ostlund H; Nielsen NH; Roos G; Emdin S; Burger AM; Seth A Oncogene; 2001 Jun; 20(27):3497-505. PubMed ID: 11429696 [TBL] [Abstract][Full Text] [Related]
4. [Use of immunohistochemical markers in the diagnosis of carcinoma of the breast]. Bussolati G Minerva Chir; 1988 Sep; 43(18 Suppl):5-7. PubMed ID: 3226595 [No Abstract] [Full Text] [Related]
5. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712 [TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-alpha and endocrine sensitivity in breast cancer. Nicholson RI; McClelland RA; Gee JM; Manning DL; Cannon P; Robertson JF; Ellis IO; Blamey RW Cancer Res; 1994 Apr; 54(7):1684-9. PubMed ID: 8137282 [TBL] [Abstract][Full Text] [Related]
7. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of c-erbB-2 protein in breast cancer tissue by enzyme immunoassay. Narita T; Funahashi H; Satoh Y; Imai T; Takagi H Jpn J Clin Oncol; 1994 Apr; 24(2):74-8. PubMed ID: 7908994 [TBL] [Abstract][Full Text] [Related]
9. [Immunohistochemical detection of estrogen and progesterone receptors in breast cancer using monoclonal antibodies: comparison with biochemical receptor analysis]. Scharl A; Vierbuchen M; Würz H Pathologe; 1989 Jan; 10(1):31-8. PubMed ID: 2646630 [No Abstract] [Full Text] [Related]
10. Male breast cancer: pathological and immunohistochemical features. Willsher PC; Leach IH; Ellis IO; Bell JA; Elston CW; Bourke JB; Blamey RW; Robertson JF Anticancer Res; 1997; 17(3C):2335-8. PubMed ID: 9245247 [TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical detection of bcl-2 and MIB-1/Ki-67 in breast cancer: retrospective analysis of 238 cases]. Sundlad AS; Ahn C; Battifora H Medicina (B Aires); 1996; 56(3):252-8. PubMed ID: 9035481 [TBL] [Abstract][Full Text] [Related]
12. [The role of epithelial antigens in diagnosis and staging of breast cancer]. Artamonova EV; Tupitsyn NN; Kadagidze ZG; Letiagin VP; Ermilova VD; Ognerubov NA; Panichenko AV; Riazantseva SN Arkh Patol; 2002; 64(6):13-5. PubMed ID: 12534220 [TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms. Wallace ML; Longacre TA; Smoller BR Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328 [TBL] [Abstract][Full Text] [Related]
14. [Steroid hormone receptor status and other immunohistochemical prognostic markers in benign and malignant diseases of the breast]. Nizze H; al-Thobhani AK; Terpe H Zentralbl Chir; 1998; 123 Suppl 5():14-8. PubMed ID: 10063564 [TBL] [Abstract][Full Text] [Related]
15. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Wärnberg F; Nordgren H; Bergkvist L; Holmberg L Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of prostate-specific antigen does not correlate to other prognostic factors in breast cancer. Heyl W; Wolff JM; Biesterfeld S; Schröder W; Zitzelsberger D; Jakse G; Rath W Anticancer Res; 1999; 19(4A):2563-5. PubMed ID: 10470195 [TBL] [Abstract][Full Text] [Related]
17. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Mulligan AM; O'Malley FP; Ennis M; Fantus IG; Goodwin PJ Breast Cancer Res Treat; 2007 Nov; 106(1):39-47. PubMed ID: 17221153 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical markers as predictive tools for breast cancer. Walker RA J Clin Pathol; 2008 Jun; 61(6):689-96. PubMed ID: 18037665 [TBL] [Abstract][Full Text] [Related]
19. Differential immunohistochemical and biological profile of squamous cell carcinoma of the breast. Grenier J; Soria JC; Mathieu MC; Andre F; Abdelmoula S; Velasco V; Morat L; Besse B; Dunant A; Spielmann M; Delaloge S Anticancer Res; 2007; 27(1B):547-55. PubMed ID: 17348440 [TBL] [Abstract][Full Text] [Related]
20. Is immunohistochemistry less sensitive than quantitative reverse transcriptase polymerase chain reaction for hormone receptor status determination in breast cancer? Arnould L; Coudert B; Fumoleau P J Clin Oncol; 2009 Jun; 27(16):2733; author reply 2734-5. PubMed ID: 19380432 [No Abstract] [Full Text] [Related] [Next] [New Search]